- Home
- ICLR vs ILMN Comparison
ICLR vs ILMN Comparison
Compare ICLR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- ILMN
- Stock Information
- Founded
- ICLR 1990
- ILMN 1998
- Country
- ICLR Ireland
- ILMN United States
- Employees
- ICLR N/A
- ILMN N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- ILMN Medical Specialities
- Sector
- ICLR Health Care
- ILMN Health Care
- Exchange
- ICLR Nasdaq
- ILMN Nasdaq
- Market Cap
- ICLR 14.3B
- ILMN 15.3B
- IPO Year
- ICLR 1998
- ILMN 2000
- Fundamental
- Price
- ICLR $178.10
- ILMN $100.48
- Analyst Decision
- ICLR Buy
- ILMN Hold
- Analyst Count
- ICLR 15
- ILMN 14
- Target Price
- ICLR $211.36
- ILMN $120.29
- AVG Volume (30 Days)
- ICLR 1.0M
- ILMN 1.6M
- Earning Date
- ICLR 10-22-2025
- ILMN 10-30-2025
- Dividend Yield
- ICLR N/A
- ILMN N/A
- EPS Growth
- ICLR N/A
- ILMN N/A
- EPS
- ICLR 7.47
- ILMN 7.91
- Revenue
- ICLR $8,102,602,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- ICLR N/A
- ILMN N/A
- Revenue Next Year
- ICLR $1.68
- ILMN $2.74
- P/E Ratio
- ICLR $24.08
- ILMN $12.66
- Revenue Growth
- ICLR N/A
- ILMN N/A
- 52 Week Low
- ICLR $125.10
- ILMN $68.70
- 52 Week High
- ICLR $242.72
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- ICLR 45.22
- ILMN 55.42
- Support Level
- ICLR $173.47
- ILMN $95.85
- Resistance Level
- ICLR $198.30
- ILMN $102.31
- Average True Range (ATR)
- ICLR 7.63
- ILMN 3.92
- MACD
- ICLR -1.08
- ILMN 0.57
- Stochastic Oscillator
- ICLR 18.63
- ILMN 87.24
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.